Thu

٠, ا	JUN 0 9 2005 DATE PROPERTY REPORTS ACT OF 1995. TRANSMITTAL	no person	U.S. Patent is are required to respond to a collection Application Number Filing Date	nt and Tr	rademark ormation 0/735	<u> </u>	
1	FORM		First Named Inventor		December 15, 2003 Goodnow et al. 1635		
1			Art Unit				
(to	be used for all correspondence after initial	filing)	V	1			
			Examiner Name	A	Amy H. Bowman		
Tota	al Number of Pages in This Submission		Attorney Docket Number	2	1366	US1	
<u> </u>		ENCI	LOSURES (Check all that	apply)		
	Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s)	ess		After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm or	Brian C. Barrey					
Individual name	Brian C. Remy					
Signature	(Brian (Keen)					
Date	June 7, 2005					
	APPTICIO ATP OF TO ANOMICOIONIMAN INC					

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Brian C. Remy		
Signature	Buar Con	Date	June 7, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

Goodnow et al.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Application No.: 10/735,991 Group: 1635

Filed: December 15, 2003 Examiner: Amy H. Bowman

For: SEQUENCE #115 AS A TARGET FOR IDENTIFYING

WEIGHT MODULATING COMPOUNDS

RESPONSE TO RESTRICTION REQUIREMENT

Nutley, New Jersey 07110 June 7, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants respectfully request consideration of the following remarks in response to the restriction requirement issued May 12, 2005 in connection with the above-identified application.

Claims 1-36 are pending. The Examiner is requiring the Applicants to elect a single group from groups I - XIV as set forth in the office action for prosecution on the merits.

The Examiner asserts that groups I – XIV are distinct, each from the other for the reasons set forth in the Office Action and that to examine the application

Application No.: 10/735,991 Filed: December 15, 2003

without restriction would impose an undue burden on the Examiner and the Patent Office resources.

The Applicants hereby provisionally elect with traverse group I (Claims 1, 3, 5, 14, 19, 25, 28, 30 and 33) drawn to a method of identifying compounds useful for modulating body weight, the method comprising contacting a test compound with a mammalian sequence #115 and identifying a compound that binds to mammalian sequence #115. However, the Applicants respectfully traverse this restriction requirement for the following reasons.

The Applicants do not believe a serious burden exists for the Examiner to search and examine groups I-XIV together since all of these groups are apparently classified in the exact same class (514) and subclass (44). The Applicants performed a search of class 514 and subclass 44 on the USPTO website and do not believe this class and subclass contain an undue number of references that would result in a serious burden to the Examiner if groups I-XIV were searched and examined together. All of the claims in all of the groups are limited to some type of G protein coupled receptor (mammalian sequence #115) limitation, which would apparently have to be a search term in every search of every group. Using the G protein coupled receptor or its synonyms as broad search term(s) should produce only a limited number of references for the Examiner to analyze.

Thus, for the above reasons, the Applicants respectfully request that the restriction requirement be withdrawn.

Application No.: 10/735,991 Filed: December 15, 2003

No fees are believed due with the filing of this response; however, authorization is hereby given to charge any fees due, or credit any overpayment, to Deposit Account No. 08-2525.

Respectfully submitted,

Brian C. Remy

Attorney for Applicant(s)

(Reg. No. 48,176) 340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-6516

Telefax: (973) 235-2363

157532